1)Perzborn E, et al:The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 10:61-75, 2011
2)EINSTEIN Investigators, et al:Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499-2510, 2010
3)EINSTEIN-PE Investigators, et al:Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287-1297, 2012
4)Agnelli G, et al:Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799-808, 2013
5)Hokusai-VTE Investigators, et al:Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406-1415, 2013
6)Büller HR, et al:Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702, 2003
7)Nakamura M, et al:Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J 75:1424-1432, 2011
8)Konstantinides SV, et al:2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033-3069, 2014
9)Kearon C, et al:Antithrombotic therapy for VTE disease;CHEST guideline and expert panel report. Chest 149:315-352, 2016
10)Aujesky D, et al:Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172:1041-1046, 2005
11)Barnes GD, Kurtz B:Direct oral anticoagulants;Unique properties and practical approaches to management. Heart 102:1620-1626, 2016